Coya Therapeutics Inc Dossier
|
SectorHealth Care IndustryBiotechnology Beta (adjusted)0.76 Intrinsic Value $6.94median of 2 methodsbased on filings through 30 Jun 2026 Market Price $4.73Price as of 1 Oct 2026 UndervaluedIntrinsic value is 47% above the market price −50% · IV below pricenear fair value ±15%IV above price · +50% Data confidence Sign in to view data confidence Market Cap $111M Enterprise Value $67.8M Shares Outstanding 23.1M diluted Next Earnings Date11 Nov 2026 All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference. ThesisStreet consensus, scenarios, merits, risks, and invalidation triggers Thesis Summary Coya Therapeutics is a clinical-stage biotechnology company pioneering combination-based regulatory T cell (Treg) therapies to target systemic inflammation and neuroinflammation. Its lead asset, COYA 302, is a promising 'pipeline-in-a-product' combining low-dose IL-2 and CTLA4-Ig. With a robust cash position of approximately $51 million as of Q1 2026, a runway extending into H2 2027, and key clinical catalysts in ALS and FTD expected in late 2026 and early 2027, Coya represents a high-upside opportunity in the neurodegenerative disease space. This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today. Street view · analyst 12-month targets Low · most bearish analyst$12.00 Mean target$15.21 High · most bullish analyst$18.00 Our research · scenarios, merits, risks, and invalidation triggersResearch as of 19 Jun 2026 Scenarios · 12-month scenario targets Bear CaseDownside scenario $8.0020% The Phase 2 ALSTARS trial experiences enrollment delays or fails to replicate the positive safety and efficacy signals seen in early proof-of-concept studies. High cash burn forces dilutive equity raises under unfavorable market conditions, and regulatory hurdles delay the initiation of the FTD and Parkinson's clinical programs. Base CaseCentral scenario $14.0050% Coya successfully completes enrollment for the ALSTARS Phase 2 trial in 2H 2026 and initiates the Phase 2a FTD trial. Clinical data continues to support the safety and biomarker-regulatory profile of COYA 302. The company maintains its cash runway into H2 2027, achieving steady progress toward clinical milestones with moderate valuation appreciation in line with consensus targets. Bull CaseUpside scenario $18.0030% COYA 302 demonstrates outstanding efficacy in the ongoing Phase 2 ALSTARS trial for ALS, leading to rapid conditional FDA approval by 2028. Strategic partnerships with major pharmaceutical companies are expanded, unlocking significant non-dilutive milestone payments and validating the Treg platform across multiple indications including Alzheimer's and Parkinson's. Scenarios are anchored to street consensus at the research date, with our probabilities and rationale. Key Investment Merits
Key Investment Risks
Thesis Invalidation Triggers
All scenarios are estimates and subject to change. Past performance is not indicative of future results. Quality Pillars MembersThis section is available to registered members. Create a free account or sign in to unlock the full breakdown. Explore this dossierValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework. |